使用原始和表面修饰的羟基磷灰石纳米颗粒进行结肠癌的先进靶向药物递送：合成、表征及pH响应性释放
Advanced Targeted Drug Delivery for Colon Cancer Using Pristine and Surface-modified Hydroxyapatite Nanoparticles: Synthesis, Characterization, and pH-Responsive Release
AI总结：
本研究合成并表征了羟基磷灰石纳米颗粒（HANs）作为抗癌药物递送载体，体外实验证明其具有高效载药和持续释放能力，为结肠癌靶向治疗提供了高效低毒的新策略。
摘要：
羟基磷灰石纳米颗粒（HANs）已成为治疗结肠癌的靶向药物递送的有前途的候选材料，结肠癌仍然是全球癌症相关死亡的主要原因之一。在本研究中，我们合成并表征了HANs，以评估其作为抗癌药物的递送载体用于专门针对结肠癌治疗的潜力。通过各种体外实验，包括药物装载效率和释放动力学，我们证明了HANs表现出高效的药物装载能力和持续释放行为，这些特性共同有助于增强对结肠癌细胞的治疗效果。研究结果突出了HANs作为化疗药物靶向递送多功能平台的潜力，提供了一种新方法，该方法可以提高治疗 efficacy，同时由于颗粒的生物相容性而将副作用降至最低。未来的研究应集中于体内研究和临床转化，以进一步验证HANs作为药物载体在癌症治疗中的潜力。
英文摘要：
Hydroxyapatite nanoparticles (HANs) have emerged as a promising candidate for targeted drug delivery in the treatment of colon cancer, a disease that remains one of the leading causes of cancer-related deaths globally. In this study, we synthesized and characterized HANs for their potential use as drug delivery vehicle for anticancer drugs specifically targeting colon cancer treatment. Through various in vitro assays, including drug loading efficiency, release kinetics, we demonstrated that HANs exhibit efficient drug loading capacity, and sustained release behavior, which could collectively contribute to enhanced therapeutic outcomes against colon cancer cells. The findings highlight the potential of HANs to serve as a versatile platform for the targeted drug delivery of chemotherapeutic agents, offering a novel approach that could improve treatment efficacy while minimizing side effects due to biocompatibility of the particles. Future research should focus on in vivo studies and clinical translation to further validate the potential of HANs in cancer therapy as drug carrier.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
